Regeneron Pharmaceuticals (REGN)
Create an AlertRegeneron Pharmaceuticals Enterprise Value:
23.71B for June 18, 2013Regeneron Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| June 18, 2013 | 23.71B |
| June 17, 2013 | 22.79B |
| June 14, 2013 | 23.21B |
| June 13, 2013 | 23.46B |
| June 12, 2013 | 23.26B |
| June 11, 2013 | 24.38B |
| June 10, 2013 | 24.76B |
| June 7, 2013 | 25.22B |
| June 6, 2013 | 24.70B |
| June 5, 2013 | 22.49B |
| June 4, 2013 | 22.81B |
| June 3, 2013 | 23.12B |
| May 31, 2013 | 23.69B |
| May 30, 2013 | 24.70B |
| May 29, 2013 | 24.26B |
| May 28, 2013 | 24.63B |
| May 24, 2013 | 24.52B |
| May 23, 2013 | 24.96B |
| May 22, 2013 | 25.70B |
| May 21, 2013 | 25.46B |
| May 20, 2013 | 25.82B |
| May 17, 2013 | 26.15B |
| May 16, 2013 | 25.92B |
| May 15, 2013 | 26.85B |
| May 14, 2013 | 27.70B |
| May 13, 2013 | 27.48B |
| May 10, 2013 | 26.79B |
| May 9, 2013 | 25.66B |
| May 8, 2013 | 25.83B |
| May 7, 2013 | 25.68B |
| May 6, 2013 | 25.74B |
| May 3, 2013 | 26.07B |
| May 2, 2013 | 24.35B |
| May 1, 2013 | 23.24B |
| April 30, 2013 | 21.07B |
| April 29, 2013 | 21.10B |
| April 26, 2013 | 21.21B |
| April 25, 2013 | 21.23B |
| April 24, 2013 | 20.63B |
| April 23, 2013 | 20.85B |
| April 22, 2013 | 20.94B |
| April 19, 2013 | 20.82B |
| April 18, 2013 | 20.24B |
| April 17, 2013 | 20.87B |
| April 16, 2013 | 21.17B |
| April 15, 2013 | 20.42B |
| April 12, 2013 | 21.08B |
| April 11, 2013 | 20.35B |
| April 10, 2013 | 19.65B |
| April 9, 2013 | 18.66B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
REGN Enterprise Value Benchmarks
| Companies | |
|---|---|
| Vertex Pharmaceuticals | 16.84B |
| Amgen | 78.31B |
| Biogen Idec | 50.14B |
REGN Enterprise Value Rankings
| Overall |
96th percentile 504 of 16770 |
| Sector |
97th percentile 40 of 1408 in Healthcare |
| Industry |
97th percentile 11 of 453 in Biotechnology |
REGN Enterprise Value Range, Past 5 Years
| Minimum | 474.32M | Jul 7 2008 |
| Maximum | 27.70B | May 14 2013 |
| Average | 5.822B |
